GaBI Journal-Generics and Biosimilars Initiative Journal

Scope & Guideline

Empowering Research in Generics and Biosimilars

Introduction

Delve into the academic richness of GaBI Journal-Generics and Biosimilars Initiative Journal with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN2033-6403
PublisherPRO PHARMA COMMUNICATIONS INT
Support Open AccessNo
CountryBelgium
TypeJournal
Convergefrom 2014 to 2024
AbbreviationGABI J / GaBI J.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPOSTBUS 10001, MOL 2400, BELGIUM

Aims and Scopes

The GaBI Journal focuses on the evolving landscape of generics and biosimilars, aiming to enhance understanding and promote discussions around the development, regulation, and utilization of these products in healthcare.
  1. Biosimilars Development and Approval Processes:
    The journal extensively covers the methodologies and regulatory frameworks for the development and approval of biosimilars, emphasizing the need for rigorous standards in clinical trials and post-market surveillance.
  2. Economic and Policy Implications:
    Research published in the journal often explores the economic aspects of biosimilars and generics, including pricing strategies, market access, and the impact of healthcare policies on patient access to these medications.
  3. Pharmacokinetics and Bioequivalence Studies:
    A significant focus is placed on pharmacokinetic studies and bioequivalence evaluations, providing insights into clinical research methodologies that ensure the safety and efficacy of biosimilars compared to their reference products.
  4. Public Perception and Acceptance:
    The journal examines the attitudes and perceptions of healthcare professionals and patients towards biosimilars, highlighting factors that influence their acceptance and usage in clinical practice.
  5. Global Perspectives on Biosimilars:
    Research articles often present a global view on biosimilars, discussing market trends, regulatory challenges, and successful case studies from various countries.
The GaBI Journal is witnessing the emergence of several key themes that reflect the changing landscape of healthcare, biosimilars, and generics.
  1. Healthcare Policy and Drug Pricing:
    Recent publications are increasingly addressing the impact of healthcare policies, such as drug price negotiations, on patient access to medications, highlighting the relevance of economic factors in the biosimilars market.
  2. Ethnic Sensitivity and Clinical Development:
    There is a growing emphasis on assessing ethnic sensitivity in clinical trials for biosimilars, which is crucial for ensuring that these products are safe and effective across diverse populations.
  3. Pharmacovigilance and Post-Market Studies:
    The focus on pharmacovigilance and long-term post-market studies is increasing, reflecting a demand for robust safety data and monitoring as biosimilars gain market share.
  4. Interchangeability and Substitution Policies:
    A trend towards more nuanced discussions around interchangeability, substitution policies, and the implications of switching between biosimilars and their reference products is emerging.
  5. Innovations in Manufacturing and Quality Control:
    There is a rising interest in innovative manufacturing processes and quality control measures for biosimilars, indicating a shift towards ensuring product integrity and reliability.

Declining or Waning

While the GaBI Journal continues to expand its focus on various aspects of biosimilars and generics, certain themes are becoming less prominent in recent publications.
  1. Traditional Generic Drug Development:
    There has been a noticeable decline in articles specifically focused on traditional generic drug development, as the journal shifts its attention more towards biosimilars and their unique challenges.
  2. Static Regulatory Frameworks:
    Research discussing established regulatory frameworks without innovative updates or challenges has decreased, reflecting a transition towards more dynamic discussions on evolving regulations in the biosimilar space.
  3. Single-Country Case Studies:
    Publications that focus solely on case studies from individual countries have become less frequent, as the journal increasingly emphasizes comparative studies and global perspectives.
  4. Historical Analysis of Drug Markets:
    Fewer articles are dedicated to historical analyses of drug markets, indicating a shift towards more current and forward-looking discussions regarding biosimilars and generics.

Similar Journals

CLINICAL THERAPEUTICS

Exploring the intersection of research and clinical excellence.
Publisher: ELSEVIERISSN: 0149-2918Frequency: 12 issues/year

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.

DRUGS & THERAPY PERSPECTIVES

Advancing the Frontiers of Pharmacology and Therapy
Publisher: SPRINGERNATUREISSN: 1172-0360Frequency: 12 issues/year

DRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.

Clinical Pharmacology in Drug Development

Exploring the future of drug efficacy and safety.
Publisher: WILEYISSN: 2160-7648Frequency: 6 issues/year

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.

DRUGS

Pioneering Research in Therapeutic Applications
Publisher: ADIS INT LTDISSN: 0012-6667Frequency: 18 issues/year

DRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.

Pharmacy & Pharmacology-Farmatsiya i Farmakologiya

Elevating research standards in pharmacy and pharmacology.
Publisher: PYATIGORSKII MEDIKO-FARMATSEVTICHESKII INSTISSN: 2307-9266Frequency: 6 issues/year

Pharmacy & Pharmacology-Farmatsiya i Farmakologiya is a distinguished journal published by the Pyatigorskii Mediko-Farmatsevticheskii Inst in the Russian Federation, dedicated to advancing research in the fields of pharmacy and pharmacology. Since its transition to an Open Access format in 2013, it has become an invaluable resource for researchers and professionals seeking to disseminate and access high-quality findings. With its ISSN 2307-9266 and E-ISSN 2413-2241, this journal covers a broad range of topics, providing a platform for the latest developments in pharmaceutical sciences. It is noteworthy that, as of 2023, Farmatsiya i Farmakologiya is categorized in various quartiles, with its Q2 ranking in Pharmacology (nursing) and Q3 in Pharmacy indicating its growing impact and relevance within its field. With the journal's commitment to fostering innovation and collaboration in pharmacy and pharmacology research, it serves as an essential hub for academics, practitioners, and students aiming to contribute to and stay informed about the dynamic landscape of this critical discipline.

DRUGS IN R&D

Exploring the latest breakthroughs in drug R&D.
Publisher: SPRINGER INT PUBL AGISSN: 1174-5886Frequency: 4 issues/year

DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.

Cyprus Journal of Medical Sciences

Elevating standards in medical research and inquiry.
Publisher: GALENOS PUBL HOUSEISSN: 2149-7893Frequency: 6 issues/year

Welcome to the Cyprus Journal of Medical Sciences, a distinguished publication dedicated to the advancement of medical knowledge and research. Published by GALENOS PUBL HOUSE, this journal endeavors to uphold the highest standards of scientific inquiry in the medical field. With its ISSN 2149-7893 and E-ISSN 2536-507X, the journal serves as an essential resource for researchers, healthcare professionals, and students seeking to stay abreast of innovative findings and clinical practices. Although currently not listed under Open Access, this journal prioritizes rigorous peer review and the dissemination of impactful research aimed at driving improvements in medical science. The journal welcomes submissions that cover diverse areas within the medical realm, contributing to a more profound understanding of healthcare challenges and solutions. Join us in exploring the frontiers of medical sciences and contributing to a healthier future.

Journal of Pioneering Medical Sciences

Empowering global health through open access research.
Publisher: JPMS PUBLISSN: 2309-7981Frequency: 4 issues/year

Journal of Pioneering Medical Sciences, published by JPMS PUBL in Karachi, Pakistan, stands as a vital resource in the field of medical research and practice. Established in 2012, this Open Access journal fosters the dissemination of innovative findings and groundbreaking studies that contribute to the advancement of medical science. With an ISSN of 2309-7981 and a commitment to rigorous peer-review, the journal encompasses a diverse range of topics, aiming to bridge knowledge gaps and promote interdisciplinary dialogue among healthcare professionals and researchers. Although it currently lacks an H-index, its focus on pioneering medical studies positions it as a platform for impactful contributions that can shape future healthcare policies and practices. The journal's open access policy ensures that vital research is freely available to a global audience, promoting accessibility and collaboration in the medical community.

Universitas Medica

Bridging gaps in knowledge for a healthier world.
Publisher: PONTIFICIA UNIV JAVERIANA, FAC MEDICINAISSN: 0041-9095Frequency: 4 issues/year

Universitas Medica is a prominent journal dedicated to advancing the field of medical sciences, published by the Pontificia Universidad Javeriana, Facultad de Medicina. Since its transition to an Open Access format in 2010, it has played a pivotal role in promoting the dissemination of high-quality medical research. Featuring a diverse array of studies encompassing clinical practice, public health, and medical education, Universitas Medica aims to provide researchers, healthcare professionals, and students with invaluable insights and the latest findings in medicine. With a focus on enhancing accessibility and fostering collaboration across the medical community, this journal stands out as a critical resource for those looking to stay abreast of innovations and trends. The journal is indexed under ISSN 0041-9095 and E-ISSN 2011-0839 and operates from its base in Bogotá, Colombia, contributing significantly to the scientific landscape both regionally and internationally.

Journal of Pharmaceutical Policy and Practice

Innovating policy to transform pharmaceutical practice.
Publisher: TAYLOR & FRANCIS LTDISSN: Frequency: 1 issue/year

Journal of Pharmaceutical Policy and Practice, published by Taylor & Francis Ltd, is a premier open access journal dedicated to advancing the field of pharmaceutical policy and practice. Launched in 2013, this esteemed journal has rapidly become a vital resource for researchers, practitioners, and policymakers alike, offering a critical examination of health policies and their implementation in pharmaceutical contexts. With an impressive impact factor reflecting its significance, it ranks in the Q2 category for Health Policy and Q1 in both Pharmacology, Toxicology and Pharmaceutics and Pharmacy, showcasing its high-quality contributions to the field. Accessible to a global audience since 2014, the journal disseminates innovative research findings that inform best practices, foster policy development, and enhance patient outcomes in the pharmaceutical landscape. Positioned in the UK and with strong Scopus rankings, specifically ranked #3 in Health Professions (Pharmacy), the journal serves as an essential platform for those striving to navigate the ever-evolving intersection of healthcare and pharmaceutical sciences.